Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Giant cell (temporal) arteritis.

G G Hunder1

  • 1Mayo Medical School, Mayo Clinic, Rochester, Minnesota.

Rheumatic Diseases Clinics of North America
|May 1, 1990
PubMed
Summary
This summary is machine-generated.

Giant cell arteritis is a common vasculitis that can be hard to diagnose. Early corticosteroid treatment prevents complications, but minimizing side effects requires careful dosage.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Primary central nervous system vasculitis: comparison of patients with and without cerebral amyloid angiopathy.

Rheumatology (Oxford, England)·2008
Same author

Primary CNS vasculitis with spinal cord involvement.

Neurology·2008
Same author

Cervical interspinous bursitis in active polymyalgia rheumatica.

Annals of the rheumatic diseases·2008
Same author

Laboratory investigations useful in giant cell arteritis and Takayasu's arteritis.

Clinical and experimental rheumatology·2004
Same author

Vasculitis. A collection of pearls and myths.

Rheumatic diseases clinics of North America·2001
Same author

Giant cell arteritis with low erythrocyte sedimentation rate: frequency of occurence in a population-based study.

Arthritis and rheumatism·2001
Same journal

Pulmonary Complications of Biological Therapies in Inflammatory and Autoimmune Diseases.

Rheumatic diseases clinics of North America·2026
Same journal

Artificial Intelligence and Social Determinants of Health.

Rheumatic diseases clinics of North America·2026
Same journal

Updates in Ultrasound in Rheumatology.

Rheumatic diseases clinics of North America·2026
Same journal

Health Systems Strengthening to Promote Access to Care for Rheumatic and Musculoskeletal Diseases Globally.

Rheumatic diseases clinics of North America·2026
Same journal

Rheumatology Care in an Aging World: Global Perspectives on Payment Models and Access for Older Adults.

Rheumatic diseases clinics of North America·2026
Same journal

The Future of Rheumatology Leadership in Africa: Building Capacity in Underserved Regions Through South-South Collaboration.

Rheumatic diseases clinics of North America·2026
See all related articles

Area of Science:

  • Rheumatology
  • Immunology
  • Vascular Medicine

Background:

  • Giant cell arteritis (GCA) is increasingly recognized as a prevalent form of vasculitis.
  • Variable clinical presentations and multifactorial features can complicate GCA diagnosis.
  • Prompt diagnosis and initiation of corticosteroid therapy are crucial for preventing serious vascular complications.

Purpose of the Study:

  • To highlight the diagnostic challenges associated with Giant Cell Arteritis.
  • To emphasize the importance of early corticosteroid treatment in preventing vascular occlusions.
  • To address the clinical challenge of balancing disease suppression with minimizing corticosteroid-related adverse effects.

Main Methods:

  • Review of clinical presentations and diagnostic criteria for Giant Cell Arteritis.

Related Experiment Videos

  • Analysis of treatment strategies focusing on corticosteroid efficacy and safety.
  • Discussion of the therapeutic window for corticosteroid dosing in GCA management.

    • Main Results:

    • Giant cell arteritis presents with diverse symptoms, often leading to delayed diagnosis.
    • Effective management relies on early corticosteroid administration to avert ischemic events.
    • Optimizing corticosteroid dosage is essential to mitigate long-term drug toxicity.

    Conclusions:

    • Early diagnosis and treatment of Giant Cell Arteritis are critical for patient outcomes.
    • Careful titration of corticosteroids is necessary to achieve disease control while minimizing adverse effects.
    • Further research into targeted therapies may offer improved risk-benefit profiles for GCA management.